Geron (GERN)
(Real Time Quote from BATS)
$3.60 USD
+0.10 (2.86%)
Updated Apr 24, 2024 01:45 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Geron Corporation [GERN]
Reports for Purchase
Showing records 21 - 40 ( 236 total )
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
ASCO 2023 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Imetelstat Up to Bat; Takeaways from Our vNDR with GERN
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
EHA 2023 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
ASCO 2023 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Q4 Financials; NDA/MAA Filings, Commercial Preparation Take Center Stage
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Positive Topline IMerge Phase 3 Results Support Potential for MDS Disease Modification; Reit. Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
IMerg-ing Highly Impressive; Increasing PT to $6
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Impressive Long Term Follow-up Data from Ph 2 Data Highlighted at ASH
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
LT Imetelstat Data Provide Strong Evidence of Disease Modification; Reit Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Imetelstat Set to Emerge as an Important New MDS Treatment Option in 2023; Reiterate Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V